62208-68-8Relevant academic research and scientific papers
Red phosphorescent compound and organic light-emitting device using same
-
Paragraph 0011, (2019/05/08)
The invention relates to a red phosphorescent compound and an organic light-emitting tube device using the same, in particular to a soluble phosphorescent compound with excellent color purity, high brightness and high light-emitting efficiency, and an organic light emitting diode (OLED) device using the same. The structural formula of the phosphorescent compound is shown as (I) (please see the specifications for the formula (I)); and in the structural formula (I), R is independently selected from the following structure (please see the specifications for the formula), wherein Ar is independently selected from one of C6-C30 aryl and C2-C30 heteroaryl, the C6-C30 aryl is selected from one of phenyl, naphthyl, xenyl, terphenyl and phenanthryl, and the C2-C30 heteroaryl is selected from one ofpyridyl, bipyridyl, quinolyl, isoquinolyl, phenanthroline and triazinyl. According to the phosphorescent compound, the chemical formula shown as the formula (I) is used as a light-emitting layer of the OLED device, and the phosphorescent compound has the excellent color purity, excellent brightness, and the prolonged durability effect.
COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME
-
Paragraph 0273; 0274; 0275; 0276, (2019/12/13)
The present specification provides a compound represented by chemical formula 1 and an organic light emitting device comprising the same. The compound described in the specification can be used as a material of an organic material layer of the organic light emitting device. The organic light emitting device comprising the compound of the present invention can improve efficiency, lower driving voltage, and improve lifespan characteristics.COPYRIGHT KIPO 2020
Novel compound and organic light-emitting component containing the same
-
Paragraph 0160-0163, (2018/04/28)
The invention provides a novel indenocarbazole compound and an organic light-emitting component containing the same.
Novel hetero-cyclic compound and organic light emitting device comprising the same
-
Paragraph 0163-0166, (2018/06/15)
The present invention refers to novel heterocyclic compound and organic light emitting number including [...] substrate. (by machine translation)
Novel hetero-cyclic compound and organic light emitting device comprising the same
-
Paragraph 0251-0254, (2018/04/03)
Provided are a novel heterocyclic compound and an organic light emitting device comprising the same. A compound represented by chemical formula 1 can be used as a material for an organic layer in an organic light emitting device, thereby being capable of improving efficiency, having low driving voltage and/or improving lifespan properties of an organic light emitting device.COPYRIGHT KIPO 2018
Novel hetero-cyclic compound and organic light emitting device comprising the same
-
Paragraph 0235; 0236; 0237, (2018/04/03)
Provided are a novel heterocyclic compound and an organic light emitting device comprising the same. A compound represented by chemical formula 1 can be used as a material for an organic layer in an organic light emitting device, thereby being capable of improving efficiency, having low driving voltage and/or improving lifespan properties of an organic light emitting device.COPYRIGHT KIPO 2018
COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY APPARATUS
-
Paragraph 0133; 0134; 0136, (2018/08/30)
PROBLEM TO BE SOLVED: To provide: a compound for an organic optoelectronic device capable of realizing an organic optoelectronic device having high efficiency and a long life span; an organic optoelectronic device employing the compound for an organic optoelectronic device; and a display apparatus including the organic optoelectronic device. SOLUTION: A compound for an organic optoelectronic device is represented by the specified chemical formula I. The chemical formula I and descriptions of each symbol in the formula are as defined herein. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPO&INPIT
CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME
-
Paragraph 1215; 1220; 1221, (2016/10/08)
Disclosed are a condensed ring compound and an organic light emitting device comprising the condensed ring compound. The organic light emitting device comprises: a first electrode; a second electrode facing the first electrode; and an organic layer interposed between the first electrode and the second electrode, wherein the organic layer comprises the condensed ring compound.COPYRIGHT KIPO 2015
Condensed compound and organic light emitting device including the same
-
Paragraph 0393; 0397; 0398, (2016/10/09)
Disclosed are condensed ring compounds and an organic light emitting device comprising the condensed ring compounds. The organic light emitting device comprises: a first electrode; a second electrode facing the first electrode; and an organic layer interposed between the first electrode and the second electrode, wherein the organic layer comprises the condensed ring compounds.COPYRIGHT KIPO 2015
TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES
-
Page/Page column 242, (2010/06/11)
The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds^ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. ?Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis,.prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. (Formula I)
